BTG PLC (LON:BTG) Rating Reaffirmed
Stock analysts at JP Morgan Cazenove now has a GBX 680.00 TP on BTG PLC (LON:BTG). JP Morgan Cazenove and their recent TP would suggest a potential upside of 2.26 % from the company’s current stock price. The rating has been disclosed to clients in an analyst report on 14 November.
BTG plc (LON:BTG) Ratings Coverage
Among 7 analysts covering BTG PLC (LON:BTG), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. BTG PLC has GBX 900 highest and GBX 490 lowest target. GBX 694.29’s average target is 5.44% above currents GBX 658.5 stock price. BTG PLC had 41 analyst reports since May 15, 2018 according to SRatingsIntel. Peel Hunt maintained BTG plc (LON:BTG) on Tuesday, May 15 with “Hold” rating. The firm earned “Hold” rating on Tuesday, September 4 by Deutsche Bank. As per Wednesday, May 16, the company rating was maintained by JP Morgan. The rating was maintained by Peel Hunt with “Hold” on Thursday, August 9. Shore Capital maintained BTG plc (LON:BTG) on Thursday, August 9 with “Buy” rating. The rating was maintained by Shore Capital with “Buy” on Wednesday, July 18. The stock of BTG plc (LON:BTG) earned “Underperform” rating by RBC Capital Markets on Wednesday, June 20. As per Tuesday, September 4, the company rating was maintained by Peel Hunt. The stock of BTG plc (LON:BTG) earned “Underperform” rating by RBC Capital Markets on Thursday, October 4. The stock of BTG plc (LON:BTG) has “Buy” rating given on Tuesday, June 5 by Numis Securities.
The stock decreased 0.23% or GBX 1.5 during the last trading session, reaching GBX 658.5. About 1.08M shares traded or 4.32% up from the average. BTG plc (LON:BTG) has 0.00% since November 14, 2017 and is . It has underperformed by 15.62% the S&P500.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. The company has market cap of 2.55 billion GBP. It operates through three divisions: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. It has a 168.85 P/E ratio. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.